Brooklyn, NY April 11, 2024 — NinthBio proudly announces the appointment of Dr. Kurt Klimpel, PhD, MBA, as Chief Scientific Officer (CSO). This momentous addition to our team marks a significant leap forward in our pursuit of revolutionizing biotechnology through innovative DNA assembly solutions. 

Dr. Klimpel's exceptional expertise and remarkable track record in the biotech industry position him as an invaluable asset to NinthBio. With over two decades of experience, Dr. Klimpel has demonstrated a remarkable ability to drive scientific innovation and deliver tangible results. 

In his role as CSO, Dr. Klimpel will spearhead our research and development efforts, leading a team dedicated to pushing the boundaries of what is possible in biotech. His leadership will propel Homology Path, our flagship DNA design platform, to new heights, empowering researchers worldwide to accelerate their discoveries in antibody therapeutics, protein engineering, and enzyme development. 

"We are thrilled to welcome Dr. Kurt Klimpel to NinthBio," exclaimed Steven Riedmuller, Founder of NinthBio. "His appointment is a testament to our commitment to excellence and our unwavering dedication to empowering researchers with cutting-edge tools. With Dr. Klimpel leading the charge, we are poised to make even greater advancements in DNA Assembly, Recycling and Reuse." 

For media inquiries or further information, please contact: 

media@ninthbio.com 

About NinthBio: 

NinthBio is a trailblazing biotech software company dedicated to pushing the boundaries of DNA design that revolutionizes drug discovery and biotechnological research. Our flagship product, Homology Path, empowers researchers to unlock new possibilities in antibody therapeutics, protein engineering, and enzyme development, driving innovation and transforming the future of biotechnology.

‍